附件： 注：左一为公司董事会秘书张斌与调研人员合影留念。 ...

证券代码：002030 证券简称：达安基因 广州达安基因股份有限公司投资者关系活动记录表 编号：2023013 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他（） 参与单位名称及 信达证券 曹佳琳 人员姓名 时间 2023-12-20（上午10:15-上午11:30） 地点 广州市高新技术开发区科学城香山路19号（公司总部） 上市公司接待人 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 员姓名 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：公司在生化这方面增长快的原因主要是什么？ ...

Group 1: Company Overview - The main business of the company is molecular products, with subsidiaries involved in immunology and biochemistry, covering the entire field of in vitro diagnostics [1] - The company has been actively obtaining various medical device certifications [1] Group 2: Financial Status - The company currently has sufficient cash flow to support daily operations and R&D investments, with no immediate plans for refinancing [2] Group 3: Market Opportunities - The pandemic has provided both opportunities and challenges, necessitating a focus on product innovation that offers cost-effective solutions for the public [2] - The company aims to diversify its product line through technological innovation to meet varying consumer needs and expand market share [2] Group 4: International Expansion - The company has exported PCR products to over 140 countries and has a complete product chain consisting of core raw materials, reagents, instruments, and supporting consumables [2] - Future plans include continued active exploration and expansion into overseas markets [2]

附件： 注：左一为公司董事会秘书张斌与调研人员合影留念。 ...

附件： 注：右一为公司董事会秘书张斌与调研人员合影留念。 ...

Group 1: Company Overview - Da An Gene has focused on molecular diagnostic technology since its establishment, achieving significant research results and numerous product certifications [1] - The company provides reliable diagnostic solutions for clinical and related fields, with many products widely applied to safeguard public health [1] Group 2: Financial Performance - Da An Gene raised approximately 160 million during its IPO and has not conducted further financing since then [2] - Cumulative cash dividends exceed 4.5 billion since the company went public in 2004 [2] Group 3: Market Strategy - The company aims to strengthen collaborations with hospitals and medical institutions to better understand customer needs and provide more clinical diagnostic solutions [2] - Da An Gene will continue to invest in product research and development to enhance product cost-effectiveness and fulfill social responsibilities [2] Group 4: Competitive Advantage - Da An Gene has developed a complete, domestically leading nucleic acid testing technology supply chain, enabling rapid product development and large-scale production [2] - The company is committed to applying its products and technologies in clinical settings, distinguishing itself from other IVD companies [2]

证券代码：002030 证券简称：达安基因 广州达安基因股份有限公司投资者关系活动记录表 编号：2023010 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他（） 国泰君安 孙超先 肖天莱 朱建华 王灿 参与单位名称及 元朔投资 梁艳仪 人员姓名 时间 2023-11-23（上午10:15-上午 11:30） 地点 广州市高新技术开发区科学城香山路19 号（公司总部） 上市公司接待人 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 员姓名 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：公司现在具有充足的现金流，是否考虑未来做一些并 ...

附件： 注：左三为公司董事会秘书张斌与调研人员合影留念。 ...

Group 1: Company Performance and Pricing Strategy - The initial price of the company's COVID-19 products was over 100 yuan, which has decreased to over 3 yuan after several rounds of large-scale procurement [1] - The company has maintained good financial performance despite the declining product prices [1][2] - The reduction in production costs is attributed to large-scale production and technological improvements, allowing for better cost control [2] Group 2: Market Share and Product Development - The company has achieved a market share of up to 60% for some products, maintaining a high market presence since its listing in 2004 [2] - The product range includes respiratory pathogens, influenza pathogens, gastrointestinal and foodborne pathogens, reproductive health, personalized tumor testing, and genetic testing [2] Group 3: Financial Outlook and Strategic Plans - The decline in profit during the third quarter was primarily due to product price adjustments and operational restructuring [2] - The company is cautiously optimistic about future investments and acquisitions, focusing on market trends and technological advancements [2] - There is a growing trend in the molecular market, with potential for molecular products to gradually replace immunological or biochemical products [2][3]

附件： 注：右四为公司董事会秘书张斌与调研人员合影留念。 ...